BioWorld

Sep. 17, 2009

Neurocrine Snares $75M CEFF to Hunt for Products to License

Neurocrine Biosciences Inc. has secured a commitment from Kingsbridge Capital Ltd. to purchase shares in the company through a warrant-free equity financing that would provide up to $75 million over three years. (BioWorld Today) Read More

Pervasis Tackling PAD with $17M Round; Seeks Vascugel Partner

Commercialization Conundrum: Partnering vs. Building a FIPCO

Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's

IPOs on Parade: Anthera Seeks $70M to Fund Cardio Studies

CMS Bundling Rule: Bad News for Amgen Now, Genzyme Later

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...